AR073331A1 - DERIVADOS DE QUINOLEíNA, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL ANTAGONISMO DE GLICINA B. - Google Patents

DERIVADOS DE QUINOLEíNA, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL ANTAGONISMO DE GLICINA B.

Info

Publication number
AR073331A1
AR073331A1 ARP090103787A ARP090103787A AR073331A1 AR 073331 A1 AR073331 A1 AR 073331A1 AR P090103787 A ARP090103787 A AR P090103787A AR P090103787 A ARP090103787 A AR P090103787A AR 073331 A1 AR073331 A1 AR 073331A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
aryl
heteroaryl
alkylamino
Prior art date
Application number
ARP090103787A
Other languages
English (en)
Inventor
Dina Trifanova
Meik Sladek
Angela Bauer
Valerjans Kauss
Wojciech Danysz
Jens Nagel
Christopher Parsons
Markus Henrich
Jevgenijs Rozhkovs
Igors Starchenkovs
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR073331A1 publication Critical patent/AR073331A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)

Abstract

Derivados de quinolina y sus sales farmacéuticamente aceptables. Estos compuestos son antagonistas de glicina B y por lo tanto son utiles para el control y prevencion de diferentes trastornos, incluyendo trastornos neurologicos. Reivindicacion 1: Un compuesto caracterizado porque se selecciona entre aquellos de formula (1) donde X1 representa hidrogeno, halogeno, nitro, trifluorometilo, alquilo C1-6, alcoxi C1-6, hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, aminoalquilo C1-6, o acilamino-alquilo C1-6; X2 representa hidrogeno, halogeno, nitro, trifluorometilo, alquilo C1-6, alcoxi C1-6, aril-alcoxi C1-6, o heteroaril-alcoxi C1-6; X3 representa hidrogeno, alquilo C1-6, halogeno, nitro, o trifluorometilo; R1 representa COOH, COOR4, CONH2, CONHR5, CONR5R6 o CH2OH; R2 representa hidrogeno, CONH2, CHOH, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, hidroxi-alquilo C1-6, amino-alquilo C1-6, carboxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, carbamoilalquilo C1-6, arilo, heteroarilo, cicloalquilo C3-12, cicloalquil C3-12-alquilo C1-6, cicloalcoxi C3-12-alquilo C1-6, ariloxi-alquilo C1-6, heteroariloxi-alquilo C1-6, arilsulfanil-alquilo C1-6, heteroarilsulfanil-alquilo C1-6, aril-alquilo C1-6, heteroaril-alquilo C1-6, cicloalquil C3-12-alquilo C1-6, aril-alcoxi C1-6, heteroaril-alcoxi C1-6, aril-alcoxi C1-6-alquilo C1-6, aril-alquilsulfanil C1-6-alquilo C1-6, heteroaril-alcoxi C1-6-alquilo C1-6, heteroaril-alquilsulfanil C1-6-alquilo C1-6, arilamino-alquilo C1-6, heteroarilamino-alquilo C1-6, cicloalquil C3-12-amino-alquilo C1-6, carboxi-alquilamino C1-6-alquilo C1-6, acilamino-alquilo C1-6, arilsulfonilamino-alquilo C1-6, alquilsulfonilamino C1-6-alquilo C1-6, alquilaminocarbonil C1-6-alquilo C1-6, cicloalquil C3-12-aminocarbonilalquilo C1-6, arilaminocarbonil-alquilo C1-6, heteroarilaminocarbonil-alquilo C1-6, aril-alquilaminocarbonil C1-6-alquilo C1-6, heteroaril-alquilaminocarbonil C1-6-alquilo C1-6, hidroxi-alquilaminocarbonil C1-6-alquilo C1-6, carboxi-alquilaminocarbonil C1-6-alquilo C1-6, di-(alquil C1-6)aminocarbonil-alquilo C1-6, heteroariloxi-aril-alquilo C1-6, aril-alcoxi C1-6-aril-alquilo C1-6, heteroarilamino-aril-alquilo C1-6, aril-alquil C1-6-heteroaril-alquilo C1-6, o heteroarilamino-alquil C1-6-aril-alquilo C1-6; R3 representa hidrogeno, alquilo C1-6, hidroxi-alquilo C1-6, o carboxi-alquilo C1-6, o R2 y R3 junto con el átomo de carbono al cual están unidos representan un anillo de 3, 4, 5, 6 o 7 miembros con entre 0 y 3 heteroátomos seleccionados entre oxígeno, nitrogeno, y azufre, donde el anillo puede opcionalmente ser parcialmente insaturado y puede estar opcionalmente fusionado a un anillo arilo o heteroarilo; R4 representa alquilo C1-6, hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, di-alquilamino C1-6-alquilo C1-6, aril-alquilo C1-6 o ariloxi-alquilo C1-6; R5 y R6 que pueden ser iguales o diferentes, en forma independiente entre si representan alquilo C1-6, cicloalquilo C3-12, alquenilo C3-6, cicloalquil C3-12-alquilo C1-6, arilo, heteroarilo, aril-alquilo C1-6, o heteroaril-alquilo C1-6; o R5 y R6 pueden representar juntos -(CH2)m- donde m es 3, 4, 5 o 6, o R5 y R6 junto con el átomo de nitrogeno al que están unidos pueden representar un anillo de 4, 5, 6 o 7 miembros que puede ser saturado o insaturado, y donde el anillo además del átomo de nitrogeno puede contener un heteroátomo adicional seleccionado entre azufre, oxígeno y nitrogeno y puede estar substituido con uno o más sustituyentes seleccionados entre COOH, CONH2, CONHR5, alquilo C1-6, carboxialquilo C1-6, carbamoil-alquilo C1-6, cicloalquilo C3-12, alquenilo C2-6, cicloalquil C3-12-alquilo C1-6, arilo, heteroarilo, aril-alquilo C1-6, o heteroaril-alquilo C1-6, arilamino, heteroarilamino, aril-alquilamino C1-6, y heteroaril-alquilamino C1-6; donde el término ôarilo" significa fenilo o naftilo, o fenilo sustituido con uno o más sustituyentes seleccionados en forma independiente entre halogeno, amino, hidroxi, nitro, ciano, COOH, COOR4, CONH2, CONHR5, CONR5R6, CH2OH, trifluorometilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, heteroarilo, alcoxi C1-6, difluorometoxi, trifluorometoxi, cicloalcoxi C3-12, ariloxi, heteroariloxi, arilalcoxi C1-6, heteroaril-alcoxi C1-6, hidroxi-alquilo C1-6, carboxialquilo C1-6, carbamoil-alquilo C1-6, carboxi-alquenilo C2-6, carboxi-alquinilo C2-6, alcoxi C1-6-alquilo C1-6, hidroxi-alcoxi C1-6, alcoxi C1-6-alcoxi C1-6, carboxi-alcoxi C1-6, carboalcoxi C1-6, alquilamino C1-6, cicloalquilamino C3-12, arilamino, heteroarilamino, arilalquilamino C1-6, heteroaril-alquilamino C1-6, hidroxialquilamino C1-6, carboxi-alquilamino C1-6, alquilamino C1-6-alquilo C1-6, di-(alquil C1-6)amino, acilamino, di-(alquil C1-6)amino-alquilo C1-6, carboxi-alquilamino C1-6-alquilo C1-6, alquilamino C1-6-alcoxi C1-6, di-(alquil C1-6)amino-alcoxi C1-6, carboxialquilamino C1-6-alcoxi C1-6, alquilsulfonilamino C1-6, arilsulfonilamino, alquilsulfonilamino C1-6-alquilo C1-6, alquilaminosulfonilo C1-6, di-(alquil C1-6)aminosulfonilo, arilaminosulfonilo, heteroarilaminosulfonilo, alquilaminocarbonil C1-6-alquilo C1-6, cicloalquilaminocarbonil C3-12-alquilo C1-6, arilaminocarbonil-alquilo C1-6, heteroarilaminocarbonil-alquilo C1-6, hidroxi-alquilaminocarbonil C1-6-alquilo C1-6, carboxialquilaminocarbonil C1-6-alquilo C1-6, di(alquil C1-6)aminocarbonil-alquilo C1-6, arilalquinilo C2-6, y heteroarilalquinilo C2-6; y el término ôheteroariloö significa un anillo aromático de 5 o 8 miembros que comprende entre 1 y 4 heteroátomos seleccionados entre oxígeno, azufre y nitrogeno, o un grupo bicíclico que contiene un anillo de 5 o 6 miembros que comprende entre 1 y 4 heteroátomos seleccionados entre oxígeno, azufre y nitrogeno fusionado con un anillo benceno o con un anillo de 5 o 6 miembros que comprende entre 1 y 4 heteroátomos seleccionados entre oxígeno, azufre y nitrogeno, donde el heteroarilo está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre halogeno, amino, hidroxi, nitro ciano, COOH, COOR4, CONH2, CONHR5, CONR5R6, CH2OH, trifluorometilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, heteroarilo, alcoxi C1-6, difluorometoxi, trifluorometoxi, cicloalcoxi C3-12, ariloxi, heteroariloxi, aril-alcoxi C1-6, heteroaril-alcoxi C1-6, hidroxialquilo C1-6, carboxialquilo C1-6, carbamoil-alquilo C1-6, carboxi-alquenilo C2-6, carboxi-alquinilo C2-6, alcoxi C1-6-alquilo C1-6, hidroxi-alcoxi C1-6, alcoxi C1-6-alcoxi C1-6, carboxi-alcoxi C1-6, carboalcoxi C1-6, alquilamino C1-6, cicloalquilamino C3-12, arilamino, heteroarilamino, aril-alquilamino C1-6, heteroaril-alquilamino C1-6, hidroxi-alquilamino C1-6, carboxi-alquilamino C1-6, alquilamino C1-6-alquilo C1-6, di-(alquil C1-6)amino, acilamino, di-(alquil C1-6)amino-alquilo C1-6, carboxi-alquilamino C1-6-alquilo C1-6, alquilamino C1-6-alcoxi C1-6, di-(alquil C1-6)amino-alcoxi C1-6, carboxialquilamino C1-6-alcoxi C1-6, alquilsulfonilamino C1-6, arilsulfonilamino, alquilsulfonilamino C1-6-alquilo C1-6, alquilaminosulfonilo C1-6, di(alquil C1-6)aminosulfonilo, arilaminosulfonilo, heteroarilaminosulfonilo, alquilaminocarbonil C1-6-alquilo C1-6, cicloalquilaminocarbonil C3-12-alquilo C1-6, arilaminocarbonil-alquilo C1-6, heteroarilaminocarbonil-alquilo C1-6, hidroxi-alquilaminocarbonil C1-6-alquilo C1-6, carboxi-alquilaminocarbonil C1-6-alquilo C1-6, y di-(alquil C1-6)aminocarbonil-alquilo C1-6; e isomeros opticos, polimorfos, análogos, derivados, prodrogas y sales de adicion ácida y básica, hidratos y solvatos farmacéuticamente aceptables del mismo.
ARP090103787A 2008-09-30 2009-09-30 DERIVADOS DE QUINOLEíNA, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL ANTAGONISMO DE GLICINA B. AR073331A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19472208P 2008-09-30 2008-09-30
EP08253183 2008-09-30

Publications (1)

Publication Number Publication Date
AR073331A1 true AR073331A1 (es) 2010-10-28

Family

ID=40433670

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103787A AR073331A1 (es) 2008-09-30 2009-09-30 DERIVADOS DE QUINOLEíNA, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL ANTAGONISMO DE GLICINA B.

Country Status (5)

Country Link
US (1) US8288549B2 (es)
EP (1) EP2350014A1 (es)
AR (1) AR073331A1 (es)
TW (1) TW201026667A (es)
WO (1) WO2010037533A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012164085A1 (en) * 2011-06-03 2012-12-06 Merz Pharma Gmbh & Co. Kgaa Glycine b antagonists
WO2013030358A1 (en) * 2011-08-31 2013-03-07 Merz Pharma Gmbh & Co. Kgaa Glycine b antagonists
FR2998892B1 (fr) 2012-12-04 2015-01-02 Pf Medicament Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
TWI588128B (zh) 2015-01-13 2017-06-21 財團法人國家衛生研究院 5-甲氧基色胺酸及其衍生物及其用途
KR20240068766A (ko) * 2015-05-22 2024-05-17 비스타젠 쎄라퓨틱스, 인크. L-４-클로로키누레닌의 치료적 용도
WO2017093354A1 (en) 2015-11-30 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Nmdar antagonists for the treatment of diseases associated with angiogenesis
CN105835412B (zh) * 2016-02-05 2018-03-02 芜湖德力自动化装备科技有限公司 一种自动化纸筒压合系统以及使用其压合纸圈的方法
CN112823006B (zh) * 2018-10-17 2024-09-17 杜克大学 用作神经保护剂的醌还原酶2抑制剂
BR112022014313A2 (pt) * 2020-01-24 2022-09-20 Syngenta Crop Protection Ag Compostos heteroaromáticos bicíclicos fundidos ativos em termos pesticidas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468015A1 (en) * 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
WO2004034985A2 (en) * 2002-10-16 2004-04-29 Smithkline Beecham Corporation Chemical compounds
JP4694821B2 (ja) 2004-11-17 2011-06-08 日本碍子株式会社 ハニカム構造体成形用口金及びハニカム構造体の製造方法

Also Published As

Publication number Publication date
US20110190342A1 (en) 2011-08-04
US8288549B2 (en) 2012-10-16
TW201026667A (en) 2010-07-16
EP2350014A1 (en) 2011-08-03
WO2010037533A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
AR073331A1 (es) DERIVADOS DE QUINOLEíNA, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL ANTAGONISMO DE GLICINA B.
CY1118128T1 (el) Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
ES2315853T3 (es) Tetrahidroquinolinonas y su uso como antagonistas de receptores de glutamato metabotropico.
CY1116391T1 (el) Αιθινυλο παραγωγα ως θετικοι αλλοστερικοι ρυθμιστες του mglur5
NI200600257A (es) Nuevos compuestos.
AR047537A1 (es) Piridazinonaureas como antagonistas de integrinas
AR061815A1 (es) Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
RU2015121424A (ru) Комбинированная терапия
AR093740A1 (es) Amidas como inhibidores de pim
AR063680A1 (es) Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5.
AR068846A1 (es) Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
MA42341B2 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
PE20061156A1 (es) Derivados de benzamida como agentes inhibidores del transportador de glicina
AR061371A1 (es) Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas.
AR050698A1 (es) Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
EA200300718A1 (ru) Производные 3-индолина, которые могут применяться при лечении психиатрических и неврологических расстройств
PE20240022A1 (es) Derivados de fosforo como nuevos inhibidores de sos1
PA8589601A1 (es) Derivados de indazol como antagonistas del crf
AR078126A1 (es) Antagonistas de glicina b, composiciones farmaceuticas, usos y proceso de preparacion de los mismos
CY1116388T1 (el) 5-(φαινυλο/πυριδινυλο-αιθινυλο)-2-πυριδινο/2-πυριμιδινο-καρβοξαμιδια ως mglur5 ρυθμιστες
ECSP11011196A (es) Derivados de piperidina
AR083475A1 (es) Moduladores de receptores de glutamato metabotropicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal